-
1 × ₨ 140.00
-
1 × ₨ 167.40
-
1 × ₨ 1,400.00
-
1 × ₨ 91.14
-
1 × ₨ 535.00
-
1 × ₨ 130.00
-
1 × ₨ 112.00
-
1 × ₨ 2,450.00
-
1 × ₨ 81.00
-
1 × ₨ 800.00
-
1 × ₨ 1,155.00
-
1 × ₨ 1,180.00
-
1 × ₨ 2,400.00
-
1 × ₨ 120.00
-
1 × ₨ 545.11
-
1 × ₨ 252.00
-
1 × ₨ 496.00
-
1 × ₨ 62.50
-
1 × ₨ 300.00
-
1 × ₨ 1,485.00
-
1 × ₨ 32.09
-
1 × ₨ 1,030.00
-
1 × ₨ 256.00
-
1 × ₨ 130.00
-
1 × ₨ 6,000.00
-
1 × ₨ 850.00
-
1 × ₨ 400.00
-
1 × ₨ 120.00
-
1 × ₨ 206.00
Roll over image to zoom in
SITAPIN 50MG
₨ 277.00₨ 308.00 (-10%)
- For use as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.
- Also for use in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin or a PPARγ agonist (e.g., thiazolidinediones) when the single agent alone, with diet and exercise, does not provide adequate glycemic control.
Sitagliptin is a new oral hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. This enzyme-inhibiting drug is to be used either alone or in combination with metformin or a thiazolidinedione for control of type 2 diabetes mellitus. The drug works to competitively inhibit a protein/enzyme, dipeptidyl peptidase 4 (DPP-4), that results in an increased amount of active incretins (GLP-1 and GIP), reduced amount of release of glucagon (diminishes its release) and increased release of insulin.
Reviews
There are no reviews yet.